Exclusive Summary

• A classic first-line standard of care for epilepsy and trigeminal neuralgia, included in the WHO Model List of Essential Medicines, backed by sustainable rigid demand from over 50 million epilepsy patients globally.
• With the original patent expired for decades and complete market education, the 0.1g * 100 tablets/bottle bulk packaging offers excellent economies of scale, making it ideal for hospital public tenders and long-term retail distribution.
• Empowered by China's mature pharmaceutical manufacturing and supply chain, it offers significant cost competitive advantages while maintaining formulation quality, enabling overseas distributors to capture broader profit margins.